Oct 5, 2017 Syros Presents Biomarker Data from Its Ongoing Phase 2 Clinical Trial of SY-1425 in Genomically Defined AML and MDS Patients at ESH Conference on AML
Sep 29, 2017 Syros to Present Biomarker Data from Ongoing Phase 2 Clinical Trial of SY-1425 at ESH Conference on AML
Sep 11, 2017 Syros Presents PK and PD Data at ESMO for SY-1425, Its First-in-Class Selective RARĪ± Agonist, in Genomically Defined AML and MDS Patients
Sep 5, 2017 Syros Pharmaceuticals to Present at Morgan Stanley 15th Annual Global Healthcare Conference
Aug 31, 2017 Syros to Present PK and PD Data from Ongoing Phase 2 Clinical Trial of SY-1425 at ESMO 2017 Congress
Aug 9, 2017 Syros Reports Second Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones
Jul 21, 2017 Syros Publishes Foundational Data Supporting Ongoing Phase 2 Clinical Trial of SY-1425 for Genomically Defined AML and MDS Patients
Jun 23, 2017 Syros Presents Data at EHA Supporting Potential of SY-1425, Its First-in-Class Selective RARĪ± Agonist, in Genomically Defined AML and MDS Patients
